Mouse models of myelodysplastic syndromes

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 853-862

  Wegrzyn, Joanna ^a   Lam, Jeffrey C ^a   Karsan, Aly ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Del(5q); Mouse models; Myelodysplastic syndrome (MDS); Xenotransplantation

Indexed keywords

CD34 ANTIGEN; DICER; HOMEODOMAIN PROTEIN; JANUS KINASE 2; L3MBTL1 PROTEIN; MICRORNA; NUCLEOPORIN 98; POLYCOMB GROUP PROTEIN; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR HOXD13; TRANSCRIPTION FACTOR RUNX1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

APOPTOSIS; ASXL1 GENE; CANCER RESEARCH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME 8; CHROMOSOME DELETION; CHROMOSOME DELETION 20Q; CHROMOSOME DELETION 5; CHROMOSOME LOSS; COPY NUMBER VARIATION; CYTOPENIA; DISEASE MODEL; EZH2 GENE; GENE DELETION; GENE MUTATION; HEMATOPOIETIC STEM CELL; IDH1 GENE; IDH2 GENE; JAK2 GENE; L3MBTL1 GENE; MALIGNANT TRANSFORMATION; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE; ONCOGENE RAS; P53 GENE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RUNX1 GENE; TET2 GENE; TRANSGENIC MOUSE; XENOTRANSPLANTATION;

ANIMALS; DISEASE MODELS, ANIMAL; MICE; MYELODYSPLASTIC SYNDROMES;

EID: 79958744030     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.03.007     Document Type: Review

References (111)

1. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937-951.
2. Corey S.J., Minden M.D., Barber D.L., Kantarjian H., Wang J.C., Schimmer A.D. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007, 7(2):118-129.
3. Nilsson L., Astrand-Grundstrom I., Arvidsson I., Jacobsson B., Hellstrom-Lindberg E., Hast R., et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000, 96(6):2012-2021.
4. Nilsson L., Eden P., Olsson E., Mansson R., Astrand-Grundstrom I., Strombeck B., et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 2007, 110(8):3005-3014.
5. Steensma D.P., Bennett J.M. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006, 81(1):104-130.
6. Li X., Bryant C.E., Deeg H.J. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol 2004, 80(2):140-145.
7. Greenberg P.L. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998, 22(12):1123-1136.
8. Olney H.J., Le Beau M.M. The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Haematol 2001, 14(3):479-495.
9. Mauritzson N., Albin M., Rylander L., Billstrom R., Ahlgren T., Mikoczy Z., et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002, 16(12):2366-2378.
10. Heuser M., Yap D.B., Leung M., de Algara T.R., Tafech A., McKinney S., et al. Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. Blood 2009, 113(7):1432-1443.
11. Curtiss N.P., Bonifas J.M., Lauchle J.O., Balkman J.D., Kratz C.P., Emerling B.M., et al. Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics 2005, 85(5):600-607.
12. Perna F., Gurvich N., Hoya-Arias R., Abdel-Wahab O., Levine R.L., Asai T., et al. Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. Blood 2010, 116(15):2812-2821.
13. Wong J.C., Zhang Y., Lieuw K.H., Tran M.T., Forgo E., Weinfurtner K., et al. Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies. Blood 2010, 115(22):4524-4532.
14. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24(6):1128-1138.
15. Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol 2008, 142(5):695-708.
16. Lyons J., Janssen J.W., Bartram C., Layton M., Mufti G.J. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood 1988, 71(6):1707-1712.
17. Hirai H., Kobayashi Y., Mano H., Hagiwara K., Maru Y., Omine M., et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 1987, 327(6121):430-432.
18. Kaneko H., Misawa S., Horiike S., Nakai H., Kashima K. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 1995, 85(8):2189-2193.
19. Paquette R.L., Landaw E.M., Pierre R.V., Kahan J., Lubbert M., Lazcano O., et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993, 82(2):590-599.
20. Shih L.Y., Huang C.F., Wang P.N., Wu J.H., Lin T.L., Dunn P., et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004, 18(3):466-475.
21. Steensma D.P., Gibbons R.J., Mesa R.A., Tefferi A., Higgs D.R. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005, 74(1):47-53.
22. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106(4):1207-1209.
23. Langemeijer S.M., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., Massop M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41(7):838-842.
24. Tefferi A., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., Patnaik M.M., et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23(7):1343-1345.
25. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Masse A., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360(22):2289-2301.
26. Reindl C., Quentmeier H., Petropoulos K., Greif P.A., Benthaus T., Argiropoulos B., et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res 2009, 15(7):2238-2247.
27. Levine R.L., Carroll M. A common genetic mechanism in malignant bone marrow diseases. N Engl J Med 2009, 360(22):2355-2357.
28. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324(5929):930-935.
29. Figueroa M., Abdel-Wahab O., Lu C., Ward P., Patel J., Shih A., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18(6):553-567.
30. Gelsi-Boyer V., Trouplin V., Adelaide J., Bonansea J., Cervera N., Carbuccia N., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145(6):788-800.
31. Fisher C.L., Pineault N., Brookes C., Helgason C.D., Ohta H., Bodner C., et al. Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2009, 115(1):38-46.
32. Sanada M., Suzuki T., Shih L.Y., Otsu M., Kato M., Yamazaki S., et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009, 460(7257):904-908.
33. Dunbar A.J., Gondek L.P., O'Keefe C.L., Makishima H., Rataul M.S., Szpurka H., et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008, 68(24):10349-10357.
34. Thien C.B., Langdon W.Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001, 2(4):294-307.
35. Bejar R., Ebert B.L. The genetic basis of myelodysplastic syndromes. Hematol Oncol Clin North Am 2010, 24(2):295-315.
36. Marcondes A.M., Mhyre A.J., Stirewalt D.L., Kim S.H., Dinarello C.A., Deeg H.J. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA 2008, 105(8):2865-2870.
37. Benesch M., Platzbecker U., Ward J., Deeg H.J., Leisenring W. Expression of FLIP(Long) and FLIP(Short) in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia 2003, 17(12):2460-2466.
38. Kordasti S.Y., Afzali B., Lim Z., Ingram W., Hayden J., Barber L., et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009, 145(1):64-72.
39. Parker J.E., Mufti G.J., Rasool F., Mijovic A., Devereux S., Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000, 96(12):3932-3938.
40. Claessens Y.E., Bouscary D., Dupont J.M., Picard F., Melle J., Gisselbrecht S., et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002, 99(5):1594-1601.
41. Nagler A., Ginzton N., Negrin R., Bang D., Donlon T., Greenberg P. Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes. Leukemia 1990, 4(3):193-202.
42. Sawada K., Sato N., Tarumi T., Sakai N., Koizumi K., Sakurama S., et al. Proliferation and differentiation of myelodysplastic CD34+ cells in serum-free medium: response to individual colony-stimulating factors. Br J Haematol 1993, 83(3):349-358.
43. Chamuleau M.E., Westers T.M., van Dreunen L., Groenland J., Zevenbergen A., Eeltink C.M., et al. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica 2009, 94(4):496-506.
44. Kotsianidis I., Bouchliou I., Nakou E., Spanoudakis E., Margaritis D., Christophoridou A.V., et al. Kinetics, function and bone marrow trafficking of CD4+ CD25+ FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009, 23(3):510-518.
45. Kordasti S.Y., Ingram W., Hayden J., Darling D., Barber L., Afzali B., et al. CD4+ CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110(3):847-850.
46. Blau O., Hofmann W.K., Baldus C.D., Thiel G., Serbent V., Schumann E., et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol 2007, 35(2):221-229.
47. Lopez-Villar O., Garcia J.L., Sanchez-Guijo F.M., Robledo C., Villaron E.M., Hernandez-Campo P., et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. Leukemia 2009, 23(4):664-672.
48. Ramakrishnan A., Awaya N., Bryant E., Torok-Storb B. The stromal component of the marrow microenvironment is not derived from the malignant clone in MDS. Blood 2006, 108(2):772-773.
49. Deeg H.J., Beckham C., Loken M.R., Bryant E., Lesnikova M., Shulman H.M., et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 2000, 37(3-4):405-414.
50. Kogan S.C., Ward J.M., Anver M.R., Berman J.J., Brayton C., Cardiff R.D., et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 2002, 100(1):238-245.
51. Steensma D.P., Dewald G.W., Hodnefield J.M., Tefferi A., Hanson C.A. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?. Leuk Res 2003, 27(3):235-242.
52. Haase D., Germing U., Schanz J., Pfeilstöcker M., Nösslinger T., Hildebrandt B., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110(13):4385-4395.
53. Nimer S.D. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 2006, 24(16):2576-2582.
54. Giagounidis A.A., Germing U., Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006, 12(1):5-10.
55. Giagounidis A.A., Germing U., Wainscoat J.S., Boultwood J., Aul C. The 5q- syndrome. Hematology 2004, 9(4):271-277.
56. Boultwood J., Fidler C., Strickson A.J., Watkins F., Gama S., Kearney L., et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002, 99(12):4638-4641.
57. Jaju R.J., Boultwood J., Oliver F.J., Kostrzewa M., Fidler C., Parker N., et al. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer 1998, 22(3):251-256.
58. Fidler C., Strickson A., Boultwood J., Waincoat J. Mutation analysis of the SPARC gene in the 5q- syndrome. Am J Hematol 2000, 64(4):p324.
59. Boultwood J., Pellagatti A., Cattan H., Lawrie C., Giagounidis A., Malcovati L., et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol 2007, 139(4):578-589.
60. Dai X.M., Ryan G.R., Hapel A.J., Dominguez M.G., Russell R.G., Kapp S., et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002, 99(1):111-120.
61. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008, 451(7176):335-339.
62. Lai F., Godley L.A., Joslin J., Fernald A.A., Liu J., Espinosa R., et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics 2001, 71(2):235-245.
63. Joslin J.M., Fernald A.A., Tennant T.R., Davis E.M., Kogan S.C., Anastasi J., et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007, 110(2):719-726.
64. Liu T.X., Becker M.W., Jelinek J., Wu W.S., Deng M., Mikhalkevich N., et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007, 13(1):78-83.
65. Lane S.W., Sykes S.M., Al-Shahrour F., Shterental S., Paktinat M., Lo Celso C., et al. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood 2010, 115(17):3489-3497.
66. Qian Z., Chen L., Fernald A.A., Williams B.O., Le Beau M.M. A critical role for Apc in hematopoietic stem and progenitor cell survival. J Exp Med 2008, 205(9):2163-2175.
67. Grisendi S., Bernardi R., Rossi M., Cheng K., Khandker L., Manova K., et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005, 437(7055):147-153.
68. Sportoletti P., Grisendi S., Majid S.M., Cheng K., Clohessy J.G., Viale A., et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008, 111(7):3859-3862.
69. Wei S., Chen X., Rocha K., Epling-Burnette P.K., Djeu J.Y., Liu Q., et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009, 106(31):12974-12979.
70. Pellagatti A., Jadersten M., Forsblom A.M., Cattan H., Christensson B., Emanuelsson E.K., et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U.S.A 2007, 104(27):11406-11411.
71. Barlow J.L., Drynan L.F., Hewett D.R., Holmes L.R., Lorenzo-Abalde S., Lane A.L., et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2009, 16(1):59-66.
72. Dutt S., Narla A., Lin K., Mullally A., Abayasekara N., Megerdichian C., et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2010.
73. Draptchinskaia N., Gustavsson P., Andersson B., Pettersson M., Willig T., Dianzani I., et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet 1999, 21(2):169-175.
74. Danilova N., Sakamoto K., Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood 2008, 112(13):5228-5237.
75. Jädersten M., Saft L., Pellagatti A., Göhring G., Wainscoat J., Boultwood J., et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009, 94(12):1762-1766.
76. Starczynowski D., Kuchenbauer F., Argiropoulos B., Sung S., Morin R., Muranyi A., et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nature Medicine. 2010, 16:49-58.
77. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116:281-297.
78. Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J, et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood. 2010.
79. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993, 75:843-854.
80. Raaijmakers M.H., Mukherjee S., Guo S., Zhang S., Kobayashi T., Schoonmaker J.A., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010, 464:852-857.
81. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003, 425:841-846.
82. Pineault N., Buske C., Feuring-Buske M., Abramovich C., Rosten P., Hogge D.E., et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood. 2003, 101:4529-4538.
83. Choi C., Chung Y., Slape C., Aplan P. A NUP98-HOXD13 fusion gene impairs differentiation of B and T lymphocytes and leads to expansion of thymocytes with partial TCRB gene rearrangement. J Immunol. 2009, 183:6227-6235.
84. Lin Y.W., Slape C., Zhang Z., Aplan P D. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood. 2005, 106:287-295.
85. Slape C., Liu L.Y., Beachy S., Aplan P D. Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl. Blood. 2008, 112:2017-2019.
86. Slape C., Hartung H., Lin Y., Bies J., Wolff L., Aplan P. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res. 2007, 67:5148-5155.
87. Kim D.K., Kojima M., Fukushima T., Miyasaka M., Nakauchi H. Engraftment of human myelodysplastic syndrome derived cell line in transgenic severe combined immunodeficient (TG-SCID) mice expressing human GM-CSF and IL-3. Eur J Haematol. 1998, 61:93-99.
88. Benito A.I., Bryant E., Loken M.R., Sale G.E., Nash R.A., John Gass M., et al. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. Leuk Res. 2003, 27:425-436.
89. Lapidot T., Fajerman Y., Kollet O. Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis. J Mol Med. 1997, 75:664-673.
90. Nilsson L., Astrand-Grundstrom I., Anderson K., Arvidsson I., Hokland P., Bryder D., et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood. 2002, 100:259-267.
91. Kollet O., Peled A., Byk T., Ben-Hur H., Greiner D., Shultz L., et al. beta2 microglobulin-deficient (B2m(null)) NOD/SCID mice are excellent recipients for studying human stem cell function. Blood. 2000, 95:3102-3105.
92. Thanopoulou E., Cashman J., Kakagianne T., Eaves A., Zoumbos N., Eaves C. Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood. 2004, 103:4285-4293.
93. Kerbauy D.M., Lesnikov V., Torok-Storb B., Bryant E., Deeg HJ Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD/SCID-beta2-microglobulin-deficient mice after intramedullary transplantation of hematopoietic and stromal cells. Blood. 2004, 104:2202-2203.
94. Martin M.G., Welch J.S., Uy G.L., Fehniger T.A., Kulkarni S., Duncavage E.J., et al. Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice. Leukemia. 2010, 24:1662-1664.
95. Shultz L.D., Lyons B.L., Burzenski L.M., Gott B., Chen X., Chaleff S., et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005, 174:6477-6489.
96. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004, 304:104-107.
97. Kahn D., Baltimore D. Pregnancy induces a fetal antigen-specific maternal T regulatory cell response that contributes to tolerance. Proc Natl Acad Sci USA. 2010, 107:9299-9304.
98. Starczynowski D.T., Kuchenbauer F., Argiropoulos B., Sung S., Morin R., Muranyi A., et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010, 16:49-58.
99. Kelly L.M., Gilliland D.G. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002, 3:179-198.
100. Watanabe-Okochi N., Kitaura J., Ono R., Harada H., Harada Y., Komeno Y., et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood. 2008, 111:4297-4308.
101. Buonamici S., Li D., Chi Y., Zhao R., Wang X., Brace L., et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest. 2004, 114:713-719.
102. Moody J.L., Xu L., Helgason C.D., Jirik F.R. Anemia, thrombocytopenia, leukocytosis, extramedullary hematopoiesis, and impaired progenitor function in Pten+/-SHIP-/- mice: a novel model of myelodysplasia. Blood. 2004, 103:4503-4510.
103. Ma Y., Cui W., Yang J., Qu J., Di C., Amin H., et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood. 2006, 108:2726-2735.
104. Omidvar N., Kogan S., Beurlet S., le Pogam C., Janin A., West R., et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res. 2007, 67:11657-11667.
105. Wu M., Eldin K., Beaudet A. Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes. J Natl Cancer Inst. 2008, 100:1247-1259.
106. Chen M., Logan T., Hochberg M., Shelat S., Yu X., Wilding G., et al. Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. Blood. 2009, 114:4045-4053.
107. Futterer A., Campanero M.R., Leonardo E., Criado L.M., Flores J.M., Hernandez J.M., et al. Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. J Clin Invest. 2005, 115:2351-2362.
108. Minella A., Loeb K., Knecht A., Welcker M., Varnum-Finney B., Bernstein I., et al. Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo. Genes Dev. 2008, 22:1677-1689.
109. Zhou L., Nguyen A., Sohal D., Ying Ma J., Pahanish P., Gundabolu K., et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood. 2008, 112:3434-3443.
110. Lehmann S., O'Kelly J., Raynaud S., Funk S., Sage E., Koeffler H. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007, 21:1931-1936.
111. Wang J., Fernald A.A., Anastasi J., Le Beau M.M., Qian Z. Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood. 2010, 115:3481-3488.